These data suggest that antitumor immunity in prostate cancer was amplified by MAO-A deletion and inhibition of this enzyme may alleviate immune suppression in the tumor microenvironment of prostate adenocarcinoma [121]. The gene discussed is MAOA; the disease is prostate carcinoma.